Article Navigation
Article Contents
-
Abstract
-
Introduction
-
Timeline
-
Case report
-
Discussion
-
Conclusion
-
Supplementary material
-
Acknowledgements
-
References
- < Previous
- Next >
Journal Article
, Mourad Amrane Department of Cardiovascular Surgery, Georges Pompidou European Hospital and University Paris-Descartes, Sorbonne Paris-Cité, 75015 Paris, France Search for other works by this author on: Oxford Academic Gilles Soulat Department of Radiology, Georges Pompidou European Hospital and University Paris-Descartes, Sorbonne Paris-Cité, 75015 Paris, France Search for other works by this author on: Oxford Academic Alain Carpentier Department of Cardiovascular Surgery, Georges Pompidou European Hospital and University Paris-Descartes, Sorbonne Paris-Cité, 75015 Paris, France Search for other works by this author on: Oxford Academic Jérôme Jouan Department of Cardiovascular Surgery, Georges Pompidou European Hospital and University Paris-Descartes, Sorbonne Paris-Cité, 75015 Paris, France Corresponding author. Tel: +33 156092060, Fax: +33 156093604, Email: jouanjerome@hotmail.com. This case report was reviewed by Georg Goliasch and Timothy C. Tan. Search for other works by this author on: Oxford Academic
European Heart Journal - Case Reports, Volume 1, Issue 2, December 2017, ytx014, https://doi.org/10.1093/ehjcr/ytx014
Published:
20 December 2017
Article history
Received:
06 September 2017
Accepted:
26 October 2017
Published:
20 December 2017
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Mourad Amrane, Gilles Soulat, Alain Carpentier, Jérôme Jouan, Starr–Edwards aortic valve: 50+ years and still going strong: a case report, European Heart Journal - Case Reports, Volume 1, Issue 2, December 2017, ytx014, https://doi.org/10.1093/ehjcr/ytx014
Close
Search
Close
Search
Advanced Search
Search Menu
Abstract
The advent of the Starr–Edwards mechanical valve marked the beginning of the modern era for heart valve replacement. Nowadays, this valve has been supplanted by lower profile bileaflet mechanical prostheses that are considered to have better haemodynamics, lesser risk of thrombo-embolic complications, and longer durability without structural prosthesis failure. These assumptions often lead physicians to face with the question of systematically replacing functional Starr–Edwards valves in patients undergoing redo operations on other valves. We report the case of a 67-year-old patient who recently underwent mitral valve replacement for symptomatic rheumatic valve disease with an excellent outcome. During the operation, the Starr–Edwards valve in the aortic position implanted 51 years earlier was found to still functioning normally hence was left in place, thereby breaking a new longevity record for a valve prosthesis.
Case report, Mechanical heart valve prosthesis, Long-term results, Redo surgery
Learning points
A new longevity record beyond 50years for valve prostheses has been set by the caged-ball mechanical Starr–Edwards aortic valve. This landmark should contribute to reassure physicians and patients on the excellent performance of this valve.
Systematic replacement of Starr–Edwards aortic valve when reoperating patients on mitral and/or tricuspid valve is not mandatory.
Introduction
The caged-ball valve created by Albert Starr and Lowell Edwards was implanted for the first time in September 1960 in the mitral position.1 It was the first valvular prosthesis produced and marketed on a large scale. Its long-term results up to 40 years have made the Starr–Edwards prosthetic valve a benchmark in the field of valvular surgery.2,3 However, if reoperation rates were reported similar to those of other more recent mechanical valves with regard to infection and prosthetic valve dehiscence,4 it has been frequently stated that the Starr–Edwards valves had a higher risk of thrombo-embolic events and of valve dysfunction. In fact, freedom from thrombo-embolic events after the implantation of Starr–Edwards valve in the aortic position varied from 74% to 87% at 10years depending mainly on the time frame of the studies, which likely reflected evolutions in anticoagulation protocols.4,5 Furthermore, in the most recent series, haemolysis and valve thrombosis rates were reported as low as 0.10% and 0.06% per patient years, respectively.6 We report a case of a 67-year-old patient who was recently reoperated on for rheumatic mitral and tricuspid valve disease and had a Starr–Edwards aortic valve implanted 51 years earlier with no valve dysfunction.
Timeline
Year | Event |
---|---|
1965 | Aortic valve replacement with a Magovern mechanical prosthesis for rheumatic valve disease |
1966 | Second cardiac procedure: aortic valve replacement with a Starr–Edwards 8A caged-ball prosthesis for Magovern valve dehiscence |
1969 | Third cardiac procedure: reinsertion of the Starr–Edwards aortic valve for partial prosthesis dehiscence and systematic ball replacement |
2009 | Atrial fibrillation and ischaemic stroke with aphasia. Complete clinical recovery within 3months |
2016 | Hospitalization for pulmonary oedema revealing severe rheumatic mitral valve insufficiency |
2017 | Fourth cardiac procedure: mitral valve replacement with a Carbomedics mechanical prosthesis associated with tricuspid valve annuloplasty. The 51-year-old Starr–Edwards aortic valve was let intact. |
Year | Event |
---|---|
1965 | Aortic valve replacement with a Magovern mechanical prosthesis for rheumatic valve disease |
1966 | Second cardiac procedure: aortic valve replacement with a Starr–Edwards 8A caged-ball prosthesis for Magovern valve dehiscence |
1969 | Third cardiac procedure: reinsertion of the Starr–Edwards aortic valve for partial prosthesis dehiscence and systematic ball replacement |
2009 | Atrial fibrillation and ischaemic stroke with aphasia. Complete clinical recovery within 3months |
2016 | Hospitalization for pulmonary oedema revealing severe rheumatic mitral valve insufficiency |
2017 | Fourth cardiac procedure: mitral valve replacement with a Carbomedics mechanical prosthesis associated with tricuspid valve annuloplasty. The 51-year-old Starr–Edwards aortic valve was let intact. |
Open in new tab
Year | Event |
---|---|
1965 | Aortic valve replacement with a Magovern mechanical prosthesis for rheumatic valve disease |
1966 | Second cardiac procedure: aortic valve replacement with a Starr–Edwards 8A caged-ball prosthesis for Magovern valve dehiscence |
1969 | Third cardiac procedure: reinsertion of the Starr–Edwards aortic valve for partial prosthesis dehiscence and systematic ball replacement |
2009 | Atrial fibrillation and ischaemic stroke with aphasia. Complete clinical recovery within 3months |
2016 | Hospitalization for pulmonary oedema revealing severe rheumatic mitral valve insufficiency |
2017 | Fourth cardiac procedure: mitral valve replacement with a Carbomedics mechanical prosthesis associated with tricuspid valve annuloplasty. The 51-year-old Starr–Edwards aortic valve was let intact. |
Year | Event |
---|---|
1965 | Aortic valve replacement with a Magovern mechanical prosthesis for rheumatic valve disease |
1966 | Second cardiac procedure: aortic valve replacement with a Starr–Edwards 8A caged-ball prosthesis for Magovern valve dehiscence |
1969 | Third cardiac procedure: reinsertion of the Starr–Edwards aortic valve for partial prosthesis dehiscence and systematic ball replacement |
2009 | Atrial fibrillation and ischaemic stroke with aphasia. Complete clinical recovery within 3months |
2016 | Hospitalization for pulmonary oedema revealing severe rheumatic mitral valve insufficiency |
2017 | Fourth cardiac procedure: mitral valve replacement with a Carbomedics mechanical prosthesis associated with tricuspid valve annuloplasty. The 51-year-old Starr–Edwards aortic valve was let intact. |
Open in new tab
Case report
In 1966, a 17-year-old patient underwent reoperation at Broussais hospital for dehiscence and dysfunction of a Magovern valve prosthesis implanted a year earlier for rheumatic aortic valvular disease. A Starr–Edwards Model 1200 prosthesis Size 8A was then implanted. Two years later, this patient had to be reoperated on for valve reinsertion and the silastic ball of the Starr–Edwards valve was also preventively changed. Over the following 50 years, she was maintained under Coumadin, had regular check-ups, and did not present any noticeable medical problems except for a permanent atrial fibrillation (AF) and an ischaemic stroke event in 2009 although the international normalized ratio (INR) was within the therapeutic window between 2.5 and 3.5. She completely recovered from the latter event within 3 days. Recently, at age 67, she became symptomatic with dyspnoea New York Heart Association (NYHA) Class III. Auscultation revealed a systolic murmur at the mitral area. Transthoracic echocardiography showed severe mitral insufficiency associated with increased left ventricular (LV) dysfunction (LV ejection fraction 42% and LV end-systolic diameter 48 mm). The mitral valve was extremely remodelled; the chordae were short and thickened, responsible for a Type IIIa posterior leaflet dysfunction. The anterior leaflet was severely retracted (height 22 mm) but also prolapsing at the level of A2 by lateral displacement of marginal chordae. On the other hand, the Starr–Edwards aortic valve prosthesis was found to function well with a mean transaortic gradient at 16.8 mmHg, peak velocity of 267 cm/s, effective orifice Area of 1.33cm2, and no significant regurgitation (Figure 1). Moderate tricuspid insufficiency (regurgitant orifice area 25mm2) and mild pulmonary arterial hypertension (systolic pulmonary arterial pressure 48mmHg) were also noted. Finally, on preoperative computed tomography scan assessment (Figure 2), an anomalous aortic origin of the circumflex artery originating from the right coronary sinus was detected.
Figure 1
Open in new tabDownload slide
Preoperative Transthoracic Echocardiography: continuous-wave Doppler evaluation of the Starr–Edwards aortic prosthesis.
Figure 2
Open in new tabDownload slide
3D Computed Tomography imaging volume rendering reconstruction of a three-chamber view showing the normal functioning of the Starr–Edwards valve in the aortic position.
The decision was made to operate on her mitral valve. Oral anticoagulation was discontinued 5 days before surgery and relayed by non-fractioned heparin when the INR was below 2.5. The intervention was performed by median sternotomy with the complete release of LV adhesions. Transoesophageal echocardiography in the operating room confirmed that the Starr valve was functioning normally and reinforced our idea of preserving this valve (see Supplementary material online, Video S1 and S2). The extracorporeal circulation was carried out by central canulation under moderate hypothermia. After aortic clamping and anterograde cold blood cardioplegia, the mitral valve was approached via the Sondergaard groove. Analysis of the mitral lesions showed that the valve vas not amenable to a repair procedure. A mitral valve replacement was then performed with a Carbomedics N°29 mechanical prosthesis combined with a tricuspid annuloplasty by a Carpentier-Edwards Physio prosthetic ring N°30. The duration of the aortic cross-clamping was 90 min. The postoperative care was uneventful, except for an episode of transient oliguria and pulmonary congestion which was favourably treated by diuretics and non-invasive ventilation.
The patient was put back on oral anticoagulation with a new targeted INR between 3 and 4. Postoperative echocardiographic assessment of the Starr–Edwards aortic prosthesis showed no functional modification compared with preoperative evaluation (see Supplementary material online, Video S3). The patient was able to leave the hospital quickly and is still doing well 5 months after the intervention.
Discussion
Since its introduction in 1960, more than 175 000 patients have received the Starr–Edwards valve in the mitral, aortic, or tricuspid position.7 The case of our patient is, to the best of our knowledge, the first reported observation of a Starr–Edwards prosthetic valve still functioning after 50 years. Only two valve-related complications occurred during the follow-up. The first was a reintervention for valve dehiscence 2years after its implantation. One can assume that this complication was due to a technical cause and not to the Starr–Edwards valve itself, because the native annulus had suffered previous damage from the dehiscence of the initial Magovern prosthesis. The change of the silastic ball had been carried out systematically, but the replaced ball did not present an abnormal infiltration pattern as described for the model 1000.8 The second was an ischaemic stroke that occurred 43 years after implantation without any additional image seen on the cardiac echography. Although thrombus from the valve prosthesis cannot be definitively excluded as the cause of stroke, the patient was also in AF. Contrary to a widely disseminated belief, the rate of thrombo-embolic events in patients with Starr–Edwards valves is not higher than that of patients with the latest generation of valves regardless of the position.9 Fortunately, this event did not have any long-term neurological consequences for our patient who fully recovered. The excellent haemodynamic stability of this valve reported in the literature10 as well as the aortic valve echocardiographic parameters led us to adopt a conservative attitude on this aortic valve. Moreover, mitral valve exposure via the Sondergaard groove was not limited by the aortic valve prosthesis protrusion towards the left atrium. This allowed us to limit the surgical time in a patient with an already significant ventricular dysfunction and thus to reduce the risk of excess mortality and complications inherent in double mitral and aortic valve replacements.11 In view of the need for anticoagulation treatment, we chose to implant a bileaflet mechanical valve in the mitral position. Preservation of the posterior subvalvular apparatus during mitral valve replacement was performed in a systematic manner for contributing to late improvement of ventricular function as recommended by many authors and European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines.12,13
Conclusion
The excellent durability of the Starr valve is further demonstrated by this observation. This might allow having a conservative attitude regarding these valves, which, in this case, has shortened the operative time, thereby contributing to a good operative outcome.
Supplementary material
Supplementary material is available at European Heart Journal - Case Reports online.
Acknowledgements
The authors are grateful to Dr Philippe Menasché and Dr Wasseem Borik for their editing contribution.
Consent: The authors confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.
Conflict of interest: A.C. is a scientific advisor at Edwards Lifesciences R&D.
Author Contributions: M.A. compiled data and was involved in writing the article. G.S. helped in editing figures. A.C. was involved in clinical and surgical management and article reviewing. J.J. contributed to clinical and surgical management, article writing, reviewing, and editing.
References
1
Starr A Edwards ML.
Mitral replacement: clinical experience with a ball-valve prosthesis
.
Ann Surg
1961
;
154
:
726
–
740
.
2
Gödje OL Fischlein T Adelhard K Nollert G Klinner W Reichart B.
Thirty-year results of Starr-Edwards prostheses in the aortic and mitral position
.
Ann Thorac Surg
1997
;
63
:
613
–
619
.
3
Saxena P Bonnichsen CR Greason KL.
Starr-Edwards aortic valve: forty-four years old and still working!
J Thorac Cardiovasc Surg
2013
;
146
:
e21
–
e22
.
4
Orszulak TA Schaff HV Puga FJ Danielson GK Mullany CJ Anderson BJ Ilstrup DM.
Event status of the Starr-Edwards aortic valve to 20 years: a benchmark for comparison
.
Ann Thorac Surg
1997
;
63
:
620
–
626
.
5
Miller DC Oyer PE Mitchell RS Stinson EB Jamieson SW Baldwin JC Shumway NE.
Performance characteristics of the Starr-Edwards model 1260 aortic valve prosthesis beyond ten years
.
J Thorac Cardiovasc Surg
1984
;
88
:
193
–
207
.
6
Lund O Pilegaard HK Ilkjaer LB Nielsen SL Arildsen H Albrechtsen OK.
Performance profile of the Starr-Edwards aortic cloth covered valve, track valve, and silastic ball valve
.
Eur J Cardiothorac Surg
1999
;
16
:
403
–
413
.
7
Matthews AM.
The development of the Starr-Edwards heart valve
.
Tex Heart Inst J
1998
;
25
:
282
–
293
.
8
Grunkemeier GL Starr A.
Late ball variance with the Model 1000 Starr-Edwards aortic valve prosthesis. Risk analysis and strategy of operative management
.
J Thorac Cardiovasc Surg
1986
;
91
:
918
–
923
.
9
Murday AJ Hochstitzky A Mansfield J Miles J Taylor B Whitley E Treasure T.
A prospective controlled trial of St. Jude versus Starr Edwards aortic and mitral valve prostheses
.
Ann Thorac Surg
2003
;
76
:
66
–
73
. discussion 73–74.
10
John S Ravikumar E John CN Bashi VV.
25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease
.
Ann Thorac Surg
2000
;
69
:
1167
–
1172
.
11
Jones JM O’Kane H Gladstone DJ Sarsam MA Campalani G MacGowan SW Cleland J Cran GW.
Repeat heart valve surgery: risk factors for operative mortality
.
J Thorac Cardiovasc Surg
2001
;
122
:
913
–
918
.
12
Komeda M David TE Rao V Sun Z Weisel RD Burns RJ.
Late hemodynamic effects of the preserved papillary muscles during mitral valve replacement
.
Circulation
1994
;
90
:
II190
–
II194
.
13
Baumgartner H Falk V Bax JJ De Bonis M Hamm C Holm PJ Iung B Lancellotti P Lansac E Muñoz DR Rosenhek R Sjögren J Tornos Mas P Vahanian A Walther T Wendler O Windecker S Zamorano JL
ESC Scientific Document Group
.
2017 ESC/EACTS guidelines for the management of valvular heart disease
.
Eur Heart J
2017
;
38
:
2739
–
2791
.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Topic:
- aorta
- aortic valve
- hemodynamics
- rheumatic disorders
- heart valves
- mitral valve replacement surgery
- longevity
- prosthesis failure
- surgical procedures, operative
- embolism
- heart valve prosthesis, artificial
- prostheses
Issue Section:
Case reports
Download all slides
Supplementary data
Supplementary data
Supplementary Video S1 - avi file
Supplementary Video S2a - avi file
Supplementary Video S2b - avi file
Comments
0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.
Advertisem*nt intended for healthcare professionals
Citations
Views
12,247
Altmetric
More metrics information
Metrics
Total Views 12,247
11,432 Pageviews
815 PDF Downloads
Since 12/1/2017
Month: | Total Views: |
---|---|
December 2017 | 81 |
January 2018 | 83 |
February 2018 | 146 |
March 2018 | 98 |
April 2018 | 84 |
May 2018 | 114 |
June 2018 | 224 |
July 2018 | 146 |
August 2018 | 197 |
September 2018 | 192 |
October 2018 | 161 |
November 2018 | 207 |
December 2018 | 206 |
January 2019 | 163 |
February 2019 | 202 |
March 2019 | 240 |
April 2019 | 198 |
May 2019 | 197 |
June 2019 | 190 |
July 2019 | 201 |
August 2019 | 175 |
September 2019 | 243 |
October 2019 | 279 |
November 2019 | 292 |
December 2019 | 213 |
January 2020 | 225 |
February 2020 | 200 |
March 2020 | 171 |
April 2020 | 82 |
May 2020 | 115 |
June 2020 | 146 |
July 2020 | 218 |
August 2020 | 142 |
September 2020 | 180 |
October 2020 | 195 |
November 2020 | 240 |
December 2020 | 202 |
January 2021 | 175 |
February 2021 | 153 |
March 2021 | 233 |
April 2021 | 170 |
May 2021 | 161 |
June 2021 | 181 |
July 2021 | 138 |
August 2021 | 148 |
September 2021 | 140 |
October 2021 | 125 |
November 2021 | 246 |
December 2021 | 133 |
January 2022 | 99 |
February 2022 | 126 |
March 2022 | 189 |
April 2022 | 148 |
May 2022 | 120 |
June 2022 | 92 |
July 2022 | 113 |
August 2022 | 121 |
September 2022 | 148 |
October 2022 | 134 |
November 2022 | 136 |
December 2022 | 117 |
January 2023 | 173 |
February 2023 | 174 |
March 2023 | 152 |
April 2023 | 206 |
May 2023 | 215 |
June 2023 | 120 |
July 2023 | 197 |
August 2023 | 107 |
September 2023 | 114 |
October 2023 | 78 |
November 2023 | 85 |
December 2023 | 76 |
January 2024 | 72 |
February 2024 | 94 |
March 2024 | 78 |
April 2024 | 54 |
May 2024 | 58 |
Altmetrics
Email alerts
Article activity alert
New issue alert
In progress issue alert
Subject alert
Receive exclusive offers and updates from Oxford Academic
Late atrioventricular groove disruption presenting 7 years after mitral valve replacement: a case report
‘Minimalist approach’ for transcatheter mitral valve replacement using intracardiac echocardiography and conscious sedation: a case series
Ruptured mitral valve abscess with mitral incompetence in culture negative infective endocarditis: case report
Aorto-right pulmonary venous fistula after mitral valve replacement for prosthetic mitral valve infective endocarditis: a case report
Related articles in PubMed
Citing articles via
Google Scholar
-
Most Read
-
Latest
More from Oxford Academic
Cardiovascular Medicine
Clinical Medicine
Medicine and Health
Books
Journals
Advertisem*nt intended for healthcare professionals